ArticleTranslational cancer research2026
Construction of a prognostic risk model based on colorectal cancer-specific ferroptosis genes and preliminary validation of FGFR4.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is one of the most common cancers worldwide. In recent years, various studies have shown that ferroptosis plays a significant role in the occurrence and development of CRC. Therefore, this study aims to explore the prognostic features of CRC associated with ferroptosis-related genes through bioinformatics analysis, and to functionally validate the target gene Methods: The data of CRC patients were obtained from The Cancer Genome Atlas (TCGA) database and intersected with Ferroptosis-related genes in GeneCards database to obtain the differentially expressed genes (DEGs). Prognostic models were constructed using Cox regression analyses and least absolute shrinkage and selection operator (LASSO) regression analysis, with comprehensive validation through Kaplan-Meier (KM) survival analysis and receiver operating characteristic (ROC) curves. A nomogram model was then constructed based on independent prognostic factors to predict patients' overall survival (OS). In addition, the potential association of FGFR4 with ferroptosis in CRC cell lines was explored by bioinformatics analysis as well as Results: A prognostic signature model was constructed based on the correlation between eight ferroptosis-related DEGs and the survival of CRC patients. Patients in the high-risk group exhibited poorer prognosis than those in the low-risk group. This signature demonstrated robust predictive performance in the training cohort and two validation cohorts. By integrating prognostic biomarkers and clinical characteristics, we established a nomogram. Additionally, expression analysis and gene set enrichment analysis (GSEA) were performed for the selected target gene Conclusions: The ferroptosis-related prognostic model for CRC established in this study exhibits favorable predictive performance. In addition, we have initially validated the relevant functions of FGFR4. Our findings provide novel insights into the prognostic assessment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.